Table 1.
Patient clinical characteristics*
| Virus (–) | Virus (+) | P Value | |
|---|---|---|---|
| n, samples | 22 | 14 | |
| n, patients | 18 | 13 | |
| Age (yr), median (range) | 21.3 (14.8–36.6) | 19.8 (14.0–36.5) | 0.987 |
| FEV1 (%), median (range) | 45 (17–89) | 34 (15–91) | 0.706 |
| BMI (kg/m2), median (range) | 20.1 (16.0–24.7) | 20.6 (15.1–21.8) | 0.626 |
| Homozygous F508del: n (% of patients) | 10 (56) | 5 (38) | 0.473 |
| CFRD: n (% of samples) | 9 (50) | 8 (62) | 0.717 |
| Bacteria: n (% of samples) | |||
| Pseudomonas aeruginosa | 12 (55) | 9 (64) | 0.731 |
| Staphylococcus aureus | 1 (5) | 1 (7) | 1.000 |
| Burkholderia cepacia complex | 2 (9) | 1 (7) | 1.000 |
| Burkholderia gladioli | 1 (5) | 2 (14) | 0.547 |
| Achromobacter sp. | 2 (9) | 0 | 0.511 |
| Stenotrophomonas maltophilia | 1 (5) | 0 | 1.000 |
| Influenza (+) | RV (+) | P Value | |
|---|---|---|---|
| n, samples | 5 | 9 | |
| n, patients | 5 | 9 | |
| Age (yr), median (range) | 26.7 (15.2–36.5) | 19.4 (14–33.3) | 0.232 |
| FEV1 (%), median (range) | 32 (16–34) | 65 (15–91) | 0.009 |
| BMI (kg/m2), median (range) | 17.0 (16.4–21.3) | 20.6 (15.1–21.8) | 0.812 |
| Homozygous F508del: n (% of patients) | 1 (20) | 4 (44) | 0.580 |
| CFRD: n (% of samples) | 4 (80) | 4 (44) | 0.301 |
| Bacteria: n (% of samples) | |||
| Pseudomonas aeruginosa | 4 (80) | 5 (55) | 0.580 |
| Staphylococcus aureus | 0 | 1 (11) | 1.000 |
| Burkholderia cepacia complex | 0 | 1 (11) | 1.000 |
| Burkholderia gladioli | 1 (20) | 1 (11) | 1.000 |
Definition of abbreviations: BMI = body mass index; CFRD = cystic fibrosis–related diabetes; RV = rhinovirus.
*
Eight subjects contributed both virus-positive and virus-negative samples; four subjects contributed two virus-negative samples and one subject contributed two virus-positive samples.